The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
David J. Benjamin, Arash Rezazadeh Kalebasty, Vinay Prasad
Topics & Concepts
MedicinePembrolizumabMetastatic Urothelial CarcinomaOncologyRegimenInternal medicineChemotherapyUrothelial carcinomaImmunotherapyCancerBladder cancerBladder and Urothelial Cancer TreatmentsEconomic and Financial Impacts of CancerCancer Immunotherapy and Biomarkers